MayoComplete Solid Tumor Panel
Test in Focus
The MayoComplete Solid Tumor Panel — Mayo Clinic Laboratories’ most comprehensive genetic profiling assay to date — uses next-generation sequencing to check for mutations in 514 cancer-related genes known to have clinical significance. In this “Test in Focus” episode of the "Answers From the Lab" podcast, co-director of Mayo Clinic’s Genomics Laboratory, Kevin Halling, M.D., Ph.D., discusses how the comprehensive panel provides wide-ranging yet highly detailed information on genetic alterations.
“It’s almost like five tests in one,” Dr. Halling says. “What we typically observe is about five to 10 clinically significant alterations per case, but sometimes many more mutations if it’s a highly mutated tumor.”
The comprehensive panel tests genes across a spectrum of cancer types, providing insights that not only establish diagnosis and predicts prognosis, but guide therapeutic decisions.
“It may be used for any patient with an advanced, solid tumor as a way of identifying which patients may benefit from either immunotherapy or specific targeted therapies,” Dr. Halling says.
Listen to learn more about how the MayoComplete Solid Tumor panel advances genetic testing to optimize treatment choices for solid tumor patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
MCSTP | MayoComplete Solid Tumor Panel
This assay requires at least 20% tumor nuclei. However, 40% tumor is preferred.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.
Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.